Ranolazine for the treatment of refractory angina in a veterans population

R. Shane Greene, Robert M. Rangel, Krystal L. Edwards, Lisa M. Chastain, Sara D. Brouse, Carlos A. Alvarez, Laura J. Collins, Emmanouil S. Brilakis, Subhash Banerjee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Pivotal ranolazine trials did not require optimization of conventional medical therapy including coronary revascularization and antianginal drug therapy prior to ranolazine use. This case series describes the use of ranolazine for the treatment of chronic stable angina refractory to maximal medical treatment in a veterans population. Results: A total of 18 patients with a median age of 66 years were identified. All patients had prior percutaneous coronary intervention and/or coronary artery bypass graft surgery; 83% had three-vessel coronary artery disease, with left main disease present in 39% of patients. Prior to initiating ranolazine, antianginal use consisted of beta blockers (94%), long-acting nitrates (83%) and calcium channel blockers (61%). Median blood pressure (116.2/61.8 mmHg) and pulse (65 beats per min) were controlled. Median preranolazine angina episodes and sublingual nitroglycerin (SLNTG) doses per week were 14 and 10, respectively, with a Canadian Cardiovascular Society (CCS) angina grade of III-IV in 67% of patients. After initiation of ranolazine, median angina episodes per week and SLNTG doses used per week decreased to 0.7 and 0, respectively, with CCS grade of III-IV declining to 17%. Of the 18 subjects enrolled, 44% had complete resolution of angina episodes. Conclusion: The addition of ranolazine to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. Ranolazine may provide an effective treatment option for revascularized patients with refractory angina.

Original languageEnglish (US)
JournalCardiovascular Revascularization Medicine
Volume13
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Veterans
Nitroglycerin
Population
Therapeutics
Drug Therapy
Stable Angina
Calcium Channel Blockers
Percutaneous Coronary Intervention
Ranolazine
Coronary Artery Bypass
Nitrates
Coronary Artery Disease
Blood Pressure
Transplants

Keywords

  • Drug therapy
  • Ranolazine
  • Refractory angina
  • Veterans affairs

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ranolazine for the treatment of refractory angina in a veterans population. / Greene, R. Shane; Rangel, Robert M.; Edwards, Krystal L.; Chastain, Lisa M.; Brouse, Sara D.; Alvarez, Carlos A.; Collins, Laura J.; Brilakis, Emmanouil S.; Banerjee, Subhash.

In: Cardiovascular Revascularization Medicine, Vol. 13, No. 2, 03.2012.

Research output: Contribution to journalArticle

Greene, R. Shane ; Rangel, Robert M. ; Edwards, Krystal L. ; Chastain, Lisa M. ; Brouse, Sara D. ; Alvarez, Carlos A. ; Collins, Laura J. ; Brilakis, Emmanouil S. ; Banerjee, Subhash. / Ranolazine for the treatment of refractory angina in a veterans population. In: Cardiovascular Revascularization Medicine. 2012 ; Vol. 13, No. 2.
@article{5deb5b5bceb946b4b06ed6f3fb977e8d,
title = "Ranolazine for the treatment of refractory angina in a veterans population",
abstract = "Background: Pivotal ranolazine trials did not require optimization of conventional medical therapy including coronary revascularization and antianginal drug therapy prior to ranolazine use. This case series describes the use of ranolazine for the treatment of chronic stable angina refractory to maximal medical treatment in a veterans population. Results: A total of 18 patients with a median age of 66 years were identified. All patients had prior percutaneous coronary intervention and/or coronary artery bypass graft surgery; 83{\%} had three-vessel coronary artery disease, with left main disease present in 39{\%} of patients. Prior to initiating ranolazine, antianginal use consisted of beta blockers (94{\%}), long-acting nitrates (83{\%}) and calcium channel blockers (61{\%}). Median blood pressure (116.2/61.8 mmHg) and pulse (65 beats per min) were controlled. Median preranolazine angina episodes and sublingual nitroglycerin (SLNTG) doses per week were 14 and 10, respectively, with a Canadian Cardiovascular Society (CCS) angina grade of III-IV in 67{\%} of patients. After initiation of ranolazine, median angina episodes per week and SLNTG doses used per week decreased to 0.7 and 0, respectively, with CCS grade of III-IV declining to 17{\%}. Of the 18 subjects enrolled, 44{\%} had complete resolution of angina episodes. Conclusion: The addition of ranolazine to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. Ranolazine may provide an effective treatment option for revascularized patients with refractory angina.",
keywords = "Drug therapy, Ranolazine, Refractory angina, Veterans affairs",
author = "Greene, {R. Shane} and Rangel, {Robert M.} and Edwards, {Krystal L.} and Chastain, {Lisa M.} and Brouse, {Sara D.} and Alvarez, {Carlos A.} and Collins, {Laura J.} and Brilakis, {Emmanouil S.} and Subhash Banerjee",
year = "2012",
month = "3",
doi = "10.1016/j.carrev.2011.06.001",
language = "English (US)",
volume = "13",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Ranolazine for the treatment of refractory angina in a veterans population

AU - Greene, R. Shane

AU - Rangel, Robert M.

AU - Edwards, Krystal L.

AU - Chastain, Lisa M.

AU - Brouse, Sara D.

AU - Alvarez, Carlos A.

AU - Collins, Laura J.

AU - Brilakis, Emmanouil S.

AU - Banerjee, Subhash

PY - 2012/3

Y1 - 2012/3

N2 - Background: Pivotal ranolazine trials did not require optimization of conventional medical therapy including coronary revascularization and antianginal drug therapy prior to ranolazine use. This case series describes the use of ranolazine for the treatment of chronic stable angina refractory to maximal medical treatment in a veterans population. Results: A total of 18 patients with a median age of 66 years were identified. All patients had prior percutaneous coronary intervention and/or coronary artery bypass graft surgery; 83% had three-vessel coronary artery disease, with left main disease present in 39% of patients. Prior to initiating ranolazine, antianginal use consisted of beta blockers (94%), long-acting nitrates (83%) and calcium channel blockers (61%). Median blood pressure (116.2/61.8 mmHg) and pulse (65 beats per min) were controlled. Median preranolazine angina episodes and sublingual nitroglycerin (SLNTG) doses per week were 14 and 10, respectively, with a Canadian Cardiovascular Society (CCS) angina grade of III-IV in 67% of patients. After initiation of ranolazine, median angina episodes per week and SLNTG doses used per week decreased to 0.7 and 0, respectively, with CCS grade of III-IV declining to 17%. Of the 18 subjects enrolled, 44% had complete resolution of angina episodes. Conclusion: The addition of ranolazine to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. Ranolazine may provide an effective treatment option for revascularized patients with refractory angina.

AB - Background: Pivotal ranolazine trials did not require optimization of conventional medical therapy including coronary revascularization and antianginal drug therapy prior to ranolazine use. This case series describes the use of ranolazine for the treatment of chronic stable angina refractory to maximal medical treatment in a veterans population. Results: A total of 18 patients with a median age of 66 years were identified. All patients had prior percutaneous coronary intervention and/or coronary artery bypass graft surgery; 83% had three-vessel coronary artery disease, with left main disease present in 39% of patients. Prior to initiating ranolazine, antianginal use consisted of beta blockers (94%), long-acting nitrates (83%) and calcium channel blockers (61%). Median blood pressure (116.2/61.8 mmHg) and pulse (65 beats per min) were controlled. Median preranolazine angina episodes and sublingual nitroglycerin (SLNTG) doses per week were 14 and 10, respectively, with a Canadian Cardiovascular Society (CCS) angina grade of III-IV in 67% of patients. After initiation of ranolazine, median angina episodes per week and SLNTG doses used per week decreased to 0.7 and 0, respectively, with CCS grade of III-IV declining to 17%. Of the 18 subjects enrolled, 44% had complete resolution of angina episodes. Conclusion: The addition of ranolazine to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. Ranolazine may provide an effective treatment option for revascularized patients with refractory angina.

KW - Drug therapy

KW - Ranolazine

KW - Refractory angina

KW - Veterans affairs

UR - http://www.scopus.com/inward/record.url?scp=84855665797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855665797&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2011.06.001

DO - 10.1016/j.carrev.2011.06.001

M3 - Article

VL - 13

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 2

ER -